Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.800
-0.070 (-2.44%)
At close: May 13, 2026, 4:00 PM EDT
2.760
-0.040 (-1.43%)
After-hours: May 13, 2026, 7:11 PM EDT
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $7.12M in the twelve months ending March 31, 2026, up 1,199.64% year-over-year. In the year 2025, Ovid Therapeutics had annual revenue of $7.25M with 1,181.27% growth.
Revenue (ttm)
$7.12M
Revenue Growth
+1,199.64%
P/S Ratio
68.15
Revenue / Employee
$309,652
Employees
23
Market Cap
484.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.25M | 6.69M | 1,181.27% |
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.58% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 299.77M |
| Fulcrum Therapeutics | 80.00M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| XOMA Royalty | 52.15M |
| Prelude Therapeutics | 12.14M |
| Ocugen | 4.47M |
| Upstream Bio | 2.85M |
OVID News
- 1 day ago - Ovid Therapeutics reports Q1 EPS (12c), consensus (11c) - TheFly
- 1 day ago - Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - GlobeNewsWire
- 22 days ago - Ovid Therapeutics files to sell 29.86M shares of common stock for holders - TheFly
- 4 weeks ago - Ovid Therapeutics Transcript: Status update - Transcripts
- 4 weeks ago - Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright - TheFly
- 5 weeks ago - Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - GlobeNewsWire
- 7 weeks ago - Ovid Therapeutics price target raised to $7 from $5 at Wedbush - TheFly
- 7 weeks ago - Ovid Therapeutics price target raised to $5 from $3 at Roth Capital - TheFly